Phase II trial of fludarabine induction followed by CAMPATH-1H [alemtuzumab] consolidation in untreated patients with B-cell chronic lymphocytic leukemia.
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2015
At a glance
- Drugs Alemtuzumab (Primary) ; Fludarabine (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 24 Jun 2015 Status changed from active, no longer recruiting to completed as per Clinicaltrials.gov.
- 01 Apr 2011 Planned End Date changed to 1 Mar 2012, according to Clinicaltrials.gov.
- 01 Apr 2011 Status changed from completed to active, no longer recruiting, according to Clinicaltrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History